Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease – Labiotech.eu (blog)
Forbes |
Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease
Labiotech.eu (blog) Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development … CRISPR Could Change The World, But Right Now $90 Million Is Enough Allergan, Editas partner on CRISPR tech in eye diseases Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseases |
